(NASDAQ:CHMA) shares saw light trading volume with 2,812 shares changing hands by the end of trading on Tuesday. Shares saw a steep decrease in trading volume of 91.50% under the normal average daily volume.
Investors are a little more bullish on shares of the company lately as indicated by the downtick in short interest. The stock saw a fall in short interest of -8.51% as of the latest report on October 13, 2017. Short shares decreased from 442,548 to 404,908 over that timeframe. With short interest at 404,908 and short average daily volume at 65,472, days to cover is 6.0 and the short interest percentage is 0.02% as of October 13.
Chiasma Inc Cmn (NASDAQ:CHMA) has been the object of insider selling activity recently. Roni Mamluk, Director reported the sale of 2,389 shares. The shares were sold on October 24th for an average price of $2.27. Mamluk now owns $0 of the stock per the Form 4 SEC filing.
These firms have modified their investment in CHMA. Wedbush Securities Inc expanded its investment by buying 5,500 shares an increase of 18.0% in the quarter. Wedbush Securities Inc now controls 36,073 shares valued at $52,000. The value of the position overall is down by 0.0%. Bridgeway Capital Management Inc augmented its stake by buying 59,300 shares an increase of 34.4%. Bridgeway Capital Management Inc owns 231,689 shares with a value of $336,000. The total value of its holdings increased 14.7%.
Blackrock Inc. reduced its holdings by selling 124,674 shares a decrease of 97.5% as of 06/30/2017. Blackrock Inc. claims 3,229 shares worth $5,000. The value of the position overall is down by 97.7%. Tower Research Capital LLC (trc) trimmed its position by selling 1,194 shares a decrease of 49.6% from 03/31/2017 to 06/30/2017. Tower Research Capital LLC (trc) now holds 1,212 shares with a value of $2,000. The value of the position overall is down by 50.0%.
The company is so far trading up since yesterday’s close of 2.05. The P/E ratio is N/A and market cap is 51.20M. As of the latest earnings report the EPS was $-1.17 with 24.38M shares currently outstanding.
Chiasma, Inc., launched on April 12, 2001, is a biopharmaceutical company. The Company is involved in developing and commercializing oral forms of therapies that are available only by injection. Using its Transient Permeability Enhancer (TPE) technology platform, the Company is developing oral therapies. The Company has completed a Phase III clinical trial of its TPE platform-based product candidate, oral octreotide capsules (trade named as MYCAPSSA) for the treatment of acromegaly, a condition that results in the body’s production of excess growth hormone. Octreotide is an analog of somatostatin, a natural inhibitor of growth hormone secretion..